Eric Venker Sells 200,000 Shares of Roivant Sciences (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $26.49, for a total value of $5,298,000.00. Following the completion of the transaction, the chief executive officer owned 1,654,597 shares in the company, valued at approximately $43,830,274.53. The trade was a 10.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Eric Venker also recently made the following trade(s):

• On Monday, January 12th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $21.92, for a total value of $4,384,000.00.
• On Wednesday, December 24th, Eric Venker sold 75,000 shares of Roivant Sciences stock. The shares were sold at an average price of $22.53, for a total transaction of $1,689,750.00.
• On Tuesday, December 23rd, Eric Venker sold 200,000 shares of Roivant Sciences stock. The stock was sold at an average price of $22.45, for a total transaction of $4,490,000.00.
• On Tuesday, December 9th, Eric Venker sold 200,000 shares of Roivant Sciences stock. The shares were sold at an average price of $20.85, for a total value of $4,170,000.00.

Roivant Sciences Stock Performance

ROIV stock traded up $0.39 during trading on Wednesday, reaching $27.48. 5,125,374 shares of the company were exchanged, compared to its average volume of 6,849,505. The stock’s 50 day moving average price is $22.95 and its 200 day moving average price is $18.62. Roivant Sciences Ltd. has a 52-week low of $8.73 and a 52-week high of $27.94. The company has a market cap of $19.67 billion, a P/E ratio of -23.49 and a beta of 1.22.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Jefferies Financial Group restated a “buy” rating and set a $30.00 price objective on shares of Roivant Sciences in a report on Monday, February 9th. Guggenheim lifted their price target on Roivant Sciences from $28.00 to $30.00 and gave the company a “buy” rating in a report on Monday, February 9th. HC Wainwright increased their price objective on shares of Roivant Sciences from $26.00 to $33.00 and gave the stock a “buy” rating in a report on Tuesday, February 10th. Wall Street Zen raised shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Leerink Partners lifted their price target on shares of Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a report on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Roivant Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $28.69.

Hedge Funds Weigh In On Roivant Sciences

Large investors have recently modified their holdings of the stock. Jones Financial Companies Lllp raised its position in shares of Roivant Sciences by 226.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after acquiring an additional 1,148 shares in the last quarter. SBI Securities Co. Ltd. raised its holdings in Roivant Sciences by 1,740.3% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after purchasing an additional 1,166 shares in the last quarter. Allworth Financial LP grew its holdings in Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock worth $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. boosted its holdings in Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock worth $28,000 after buying an additional 543 shares in the last quarter. Finally, CWM LLC boosted its position in shares of Roivant Sciences by 44.6% in the 2nd quarter. CWM LLC now owns 2,984 shares of the company’s stock valued at $34,000 after purchasing an additional 920 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.